256 related articles for article (PubMed ID: 11730946)
1. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
J Neuroimmunol; 2001 Dec; 121(1-2):102-10. PubMed ID: 11730946
[TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
[TBL] [Abstract][Full Text] [Related]
3. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis.
Zang YC; Skinner SM; Robinson RR; Li S; Rivera VM; Hutton GJ; Zhang JZ
Mult Scler; 2004 Oct; 10(5):499-506. PubMed ID: 15471364
[TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells.
Vieira PL; Heystek HC; Wormmeester J; Wierenga EA; Kapsenberg ML
J Immunol; 2003 May; 170(9):4483-8. PubMed ID: 12707324
[TBL] [Abstract][Full Text] [Related]
5. Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10.
Huang YM; Stoyanova N; Jin YP; Teleshova N; Hussien Y; Xiao BG; Fredrikson S; Link H
Clin Exp Immunol; 2001 May; 124(2):306-14. PubMed ID: 11422209
[TBL] [Abstract][Full Text] [Related]
6. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta induces the development of type 2 dendritic cells.
Huang YM; Hussien Y; Yarilin D; Xiao BG; Liu YJ; Link H
Cytokine; 2001 Mar; 13(5):264-71. PubMed ID: 11243704
[TBL] [Abstract][Full Text] [Related]
8. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells.
Radvanyi LG; Banerjee A; Weir M; Messner H
Scand J Immunol; 1999 Nov; 50(5):499-509. PubMed ID: 10564553
[TBL] [Abstract][Full Text] [Related]
9. The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta.
Shapiro S; Galboiz Y; Lahat N; Kinarty A; Miller A
J Neuroimmunol; 2003 Nov; 144(1-2):116-24. PubMed ID: 14597105
[TBL] [Abstract][Full Text] [Related]
10. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis.
Salama HH; Kolar OJ; Zang YC; Zhang J
Mult Scler; 2003 Feb; 9(1):28-31. PubMed ID: 12617264
[TBL] [Abstract][Full Text] [Related]
11. Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis.
Filion LG; Matusevicius D; Graziani-Bowering GM; Kumar A; Freedman MS
Clin Immunol; 2003 Feb; 106(2):127-38. PubMed ID: 12672403
[TBL] [Abstract][Full Text] [Related]
12. Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients.
Ruggieri M; Pica C; Lia A; Zimatore GB; Modesto M; Di Liddo E; Specchio LM; Livrea P; Trojano M; Avolio C
J Neuroimmunol; 2008 Jul; 197(2):140-6. PubMed ID: 18555539
[TBL] [Abstract][Full Text] [Related]
13. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
14. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
[TBL] [Abstract][Full Text] [Related]
15. A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern.
Ebner S; Hofer S; Nguyen VA; Fürhapter C; Herold M; Fritsch P; Heufler C; Romani N
J Immunol; 2002 Jun; 168(12):6199-207. PubMed ID: 12055233
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis: interferon-beta induces CD123(+)BDCA2- dendritic cells that produce IL-6 and IL-10 and have no enhanced type I interferon production.
Huang YM; Adikari S; Båve U; Sanna A; Alm G
J Neuroimmunol; 2005 Jan; 158(1-2):204-12. PubMed ID: 15589055
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation.
Kaliński P; Schuitemaker JH; Hilkens CM; Kapsenberg ML
J Immunol; 1998 Sep; 161(6):2804-9. PubMed ID: 9743339
[TBL] [Abstract][Full Text] [Related]
18. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis.
Putheti P; Soderstrom M; Link H; Huang YM
J Neuroimmunol; 2003 Nov; 144(1-2):125-31. PubMed ID: 14597106
[TBL] [Abstract][Full Text] [Related]
19. Effect of CXC chemokine platelet factor 4 on differentiation and function of monocyte-derived dendritic cells.
Xia CQ; Kao KJ
Int Immunol; 2003 Aug; 15(8):1007-15. PubMed ID: 12882838
[TBL] [Abstract][Full Text] [Related]
20. Monocyte-derived CD1a+ and CD1a- dendritic cell subsets differ in their cytokine production profiles, susceptibilities to transfection, and capacities to direct Th cell differentiation.
Chang CC; Wright A; Punnonen J
J Immunol; 2000 Oct; 165(7):3584-91. PubMed ID: 11034359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]